World High Life’s (OTCQB: WRHLF) wholly owned subsidiary, Love Hemp, is embracing the idea, “when life gives you lemons, make lemonade.”  In early 2020, COVID-19 turned into a global pandemic, and in an instant, created a tough environment for both businesses and consumers alike.  Tony Calamita, the CEO of Love Hemp, a London-based CBD company playing a leadership role in the development of the United Kingdom’s (UK) leading range of trusted CBD products, accepted the challenge and has capitalized on these tough times with a dramatic surge in online sales.

While the world began to lock down and shelter-in-place, Calamita’s team got creative by dedicating all of Love Hemp’s resources and team to building upon their advanced e-commerce platforms—realizing that the major retail path would be beyond their control during the pandemic.  As a result, consumers began to engage with the company in an unprecedented fashion, and Love Hemp, with its multiple e-commerce platforms, has accelerated its online brand strategy months ahead of planned targets.


And Love Hemp’s strategy and execution has worked to perfection.

World High Life announced that Love Hemp’s online sales in May 2020 eclipsed online sales figures from January 2020 by an astounding 107%.  These numbers come on the heels of month-over-month growth every single month since January.  The year 2020, while dismal for many businesses across the globe, has been a breakout campaign for Love Hemp—a company that expects the jump in sales during the pandemic to lead to longer-term gains—all while putting World High Life and its efforts to grow an investment portfolio in the legal medicinal cannabis, hemp and CBD industries, on the map as a serious competitor in these industries.

Brands, like Love Hemp, that have enjoyed a surge in online sales have most likely also enjoyed a rush of first-time customers giving them a monumental opportunity to differentiate themselves from other brands with what is a captive audience experiencing new innovative products as they’re rolled out among the already-popular choices.

Love Hemp already has over 80 products, including oils, sprays, edibles, cosmetics, and vapes, and has around 1,200 retail listings.  Combined, these products have positioned the company as one of the UK’s leading CBD and hemp product suppliers, but the company isn’t stopping there because as Love Hemp’s CEO points out, the company is always expanding its product line to meet the demands of its growing customer base.

“Love Hemp has always been passionate about creating a leading range of trusted CBD products.  Over the past few years, we have seen the demand for CBD products soar in the UK as more and more people become aware of its benefits to well-being.”  Tony Calamita continued, “New product development is at the heart of our business—we were the first functional spring water in Europe to be infused with CBD.  Oils, sprays, vapes, chocolate, jelly domes, and beauty products, including the first CBD-infused face masks and body salves, have all followed.”

One such product that illustrates Love Hemp’s desire to meet consumer demand is Love Hemp Immune.  The company successfully pushed this product to market well ahead of schedule to meet the needs of consumers.  It is an innovative product that truly confronts the current times we’re all living in, so Calamita and his team made it a priority to launch it sooner rather than later.  Love Hemp Immune is made with the highest quality ingredients, including a combination of CBD, Vitamin C, Vitamin D, and Bilberry extract.  It contains all of the essential supplements that support a healthy immune system, and the company says it’s available in both a 100 ml atomizer spray, as well as, in capsule form.

Calamita said of the early release, “We were due to launch Love Hemp Immune in the Winter of 2020, but we have worked around the clock to get it to consumers sooner—and moved forward the launch by six months—launching it in April 2020 instead.  Boosting our immune systems has rarely felt more urgent than now, and Love Hemp Immune contains the perfect combination of beneficial ingredients that will help boost the body’s natural defenses.”

Last month World High Life announced that Love Hemp is achieving its plans of growth and brand expansion with a host of notable highlights, including:

  • The Love Hemp brand (www.love-hemp.com) has secured a number of notable listings with leading retailers, such as Boots to complement its existing listings with Ocado, Holland and Barrett, and Sainsbury’s.
  • According to Alliance Healthcare, the UK’s leading distributor to pharmacies and independent retailers, the Love Hemp brand is now its best-selling CBD brand.
  • The brand is in negotiations with some of the largest retailers in the UK for multiple new product listings.
  • To support the growing demand and sales of its products, Love Hemp’s secondary online retailer, CBDOilsUK (www.cbdoilsuk.com), is expanding its product portfolio with three new brands and a renewed web presence in the near future.
  • LH Botanicals (www.lhbotanicals.com), Love Hemp’s CBD wholesale production business, is adding production capacity and new product lines with the acquisition of new machines.

Brightfield Group, the leading consumer insights and market intelligence firm for the CBD and cannabis industries said of weathering the pandemic, “Smaller brands often rely on small or local retailers to distribute the bulk of their products.  In the current environment, mass shuttering of retailers is likely to deal a death blow to many of the smaller brands in the market.  This could actually work in favor of many of the larger brands, who are better positioned to weather the storm and be able to support a robust e-comm strategy.  If they can keep the lights on over the next few months, they may be competing in a much less crowded field once we emerge from the crisis.”

Love Hemp, however, is unlike many smaller brands and has proven that it is an exception to the rule as it is not only weathering these tough times but thriving in them.  The company’s success is likely due to the infrastructure it already had in place to prosper in times like these.

Love Hemp has its own wholesale production business with LH Botanicals, which is the UK’s biggest seed-to-shelf premium CBD supplier.  It provides a complete range of CBD products for wholesale, bulk, and white label and it works with brands to formulate and develop their own finished products.  Additionally, Love Hemp has its own secondary online retailer, and it has already secured shelf space in pharmacies and with leading retailers, and the company has a team that is constantly thinking outside-the-box to develop new products and negotiate shelf space with some of the UK’s largest retailers.

Brightfield Group released new consumer research in mid-March 2020 that indicated, anxiety rated as the highest ailment among CBD users with depression and insomnia following close behind.  But, interestingly, Brightfield Group found that self-care products have become a popular topic on social media.  With much of the world in quarantine or slowly emerging from it right now, Brightfield Group says, “many are turning to self-care indulgences to keep themselves sane and even just pass the time, which is likely to help boost some CBD self-care products during quarantine time.”

Love Hemp is in a position to offer products that can help with what is ailing each of these groups.  First, all of the company’s products have certified CBD concentration and are certified to be 100% THC free.  Globally there is growing awareness about the possible health benefits of CBD oil, including for anxiety relief, as an anti-seizure solution, for pain relief, as a neuroprotective, etc., and Love Hemp even offers self-care products.

Brightfield Group has estimated significant growth over the next four years in the European market.  The firm’s research expects 400% growth in Europe’s legal cannabis market by the end of 2023, and with Love Hemp situated in the UK and succeeding, it is in an ideal position to capture a large share of that growing European market.  Read about World High Life/Love Hemp’s planned brand expansion in other global CBD markets: https://www.globenewswire.com/news-release/2020/06/15/2048074/0/en/World-High-Life-Subsidiary-Continues-Massive-Sales-Growth-in-the-UK-CBD-Market-with-Eye-to-Future-Brand-Expansion.html

To learn more about World High Life visit: https://www.worldhighlife.uk

To learn more about Love Hemp visit: https://love-hemp.com

Or to ask questions directly, call their toll-free number in North America: 1 (888) 616-WRHLF (9745)

About World High Life

World High Life PLC is an investment company with a strategic focus to invest in and/or acquire companies operating in the CBD wellness and medicinal cannabis industry.  The Company’s wholly owned subsidiary, Love Hemp Ltd., is one of the UK’s leading CBD and Hemp product suppliers and has more than 40 product lines, comprising oils, sprays and vapes, and a variety of edible and water-based CBD products.  Love Hemp has established relationships with over 1,200 stores in the UK, including leading brands such as Ocado, Holland & Barrett, and WH Smith.

About Stock Market Media Group

Stock Market Media Group is a news & media content development IR firm offering a platform for corporate stories to unfold in the media with press releases, research reports, corporate videos, radio-style CEO interviews, and feature news articles.

This article was written based on publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets, and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at www.sec.gov, where you can also find all of World High Life’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.  We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell, or offer to buy any security. Our publications about World High Life are not a recommendation to buy or sell a security.

Should Stock Market Media Group and its management own shares in the profiled company, they may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company’s profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it was remunerated one-thousand, two hundred dollars paid for by a third party (three-thousand, six hundred dollars total to date) via bank wire, to produce content related to World High Life.

Stock Market Media Group and its management do not own any shares in World High Life and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company’s stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company’s profile, our disclaimer will be updated accordingly to reflect the current position of any free trading shares received as compensation for our services.

For more information: www.stockmarketmediagroup.com.

Contact:

Stock Market Media Group

info@stockmarketmediagroup.com

Primary Logo

GlobeNewswire
June 29, 2020 – 5:30 AM PDT
News by QuoteMedia

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), announces that, further to its news releases dated December 22, 2020 and January 7, 2021 the Company has closed its non-brokered private placement financing comprising of 7,500,000 units, at $0.10 per unit, for total gross proceeds of $750,000 .

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

 Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE: RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that is has entered into an agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 20,000,000 units (the ” Equity Units “) at a price of $0.50 per Equity Unit for gross proceeds to the Company of $10,000,000 (the ” Offering “).

Keep reading... Show less

The Australian cannabis market has been maturing since medical marijuana was federally legalised in 2016.

The next year, Food Standards Australia New Zealand legalised low-THC hemp food for human consumption in Australia. The country went on to legalise medical marijuana exports in 2018, allowing medicinal marijuana products developed in Australia to be exported to licenced recipients in countries where the drug is legal.

Recreational cannabis remains federally illegal in the country, but recent legislation shows the door may be opening. In 2019, the Australian Capital Territory passed a bill allowing for the possession and growth of small amounts of cannabis for personal use. The law went into effect on January 31, 2020.

More recently, in late 2020, the Therapeutic Goods Administration greenlit the sale of low-dose cannabidiol (CBD) through over-the-counter methods without a prescription. The ruling from the Australian regulatory agency is expected to officially come into effect in February 2021.

With these and other changes in the works, Australia’s cannabis industry is projected to have long-term potential. The legal cannabis market in Oceania is expected to be worth US$1.55 billion by 2024, with Australia accounting for 79 percent of the region’s market, Prohibition Partners forecasts.

According to a study from FreshLeaf Analytics, the value of the medical market in Australia reached AU$95 million in 2020, and the firm expects revenue to jump again to over AU$150 million in 2021. In short, Australia’s role in the global cannabis industry will certainly continue to grow.

Here the Investing News Network profiles 10 ASX cannabis stocks with market caps between AU$30 million and AU$225 million. All ASX cannabis stocks below are listed in order of market capitalization from largest to smallest, with data compiled using TradingView’s stock screener on January 12, 2021.

1. Creso Pharma (ASX:CPH)

Market cap: AU$209.83 million

Creso Pharma was the first company to import medical cannabis into Australia and the first to launch these products in Switzerland for people, as well as animals. The cannabis company’s anibidiol product was the first hemp CBD complementary feed in animal health thanks to a partnership with Virbac Switzerland. Creso Pharma has also launched cannaQIX in Switzerland; it was the first CBD nutraceutical in human health.

The company’s medicinal cannabis product lines cover therapeutics, nutraceuticals, animal health, lifestyle and topicals.

2. Cann Group (ASX:CAN)

Market cap: AU$176.84 million

Cann Group provides a range of medicinal cannabis products for patients in Australia and globally. In 2017, the company was granted Australia’s first cannabis research licence, as well as the first medicinal marijuana cultivation licence. Cann Group partners with leading medical scientists in Australia to research and harness the therapeutic potential of cannabinoids, terpenes and other bioactive constituents of cannabis.

The company has secured supply agreements in global cannabis markets, including the UK, Germany and other European segments.

3. Incannex Healthcare (ASX:IHL)

Market cap: AU$166.42 million

Incannex Healthcare is a clinical-stage cannabinoid medicine company with global export capacity. It has four clinical programs underway for the development of a variety of cannabis medicinal products aimed at major unmet medical needs, including obstructive sleep apnea, traumatic brain injury/concussion, sepsis-associated acute respiratory distress syndrome and temporomandibular joint disorder.

In 2020, the company worked to advance its clinical trials. By the second half of the year, cannabinoid products accounted for Incannex’s entire revenue stream.

4. Botanix Pharmaceuticals (ASX:BOT)

Market cap: AU$131.37 million

Botanix Pharmaceuticals has a product pipeline that includes three advanced clinical programs using synthetic cannabidiol for the topical treatment of serious skin diseases and for antimicrobial applications. The company also has an exclusive licence to use a proprietary drug-delivery system called Permetrex for direct skin delivery of pharmaceuticals.

Botanix Pharmaceuticals’ programs are focused on treating acne, rosacea, atopic dermatitis and microbial infection. The company secured a clear development path for its BTX 1801 synthetic cannabidiol antimicrobial product after the successful completion of a pre-investigational new drug meeting with the US Food and Drug Administration.

5. Althea Group Holdings (ASX:AGH)

Market cap: AU$114.2 million

Althea Group Holdings takes the concept of medical cannabis a step further with its work as a pharmaceutical-grade cannabis supplier. In addition to offering relief through accessible medical cannabis, the company is implementing components of the plant in its research on advanced drugs.

Althea has successfully expanded into the global cannabis market with a wholesale supply agreement to import a range of Althea-branded finished products for sale and distribution in South Africa beginning in Q2 2021. This agreement came on the heels of the news that the company is slated to become the first commercial supplier of Australian medicinal cannabis extract products to the German market, with all necessary licences for sale and distribution granted by the German government.

6. Zelira Therapeutics (ASX:ZLD)

Market cap: AU$113.79 million

Zelira Therapeutics’ efforts are on unmet clinical needs and on using medicinal cannabis to treat a range of diseases and disorders. Its most common target areas include pain, anxiety and sleep.

Zelira is largely focused on developing treatment options using plant-based medicinal marijuana, and currently has three clinical-stage programs with a focus on insomnia, autism and opioid reduction. The company is also conducting a pre-clinical research program to test cannabinoids in breast, brain and pancreatic cancer.

7. Medlab Clinical (ASX:MDC)

Market cap: AU$75.51 million

Medlab Clinical is a medical research and development company focused on novel biotherapeutics such as nutraceuticals and pharmaceuticals. The company is also developing pharmaceutical cannabis products.

In early 2020, Medlab Clinical launched the NanaBis Observation Study in Australia. NanaBis is a cannabis-based pain treatment drug that may prove useful as an alternative to opioid medication. It is also being used to investigate cancer pain management.

8. BOD Australia (ASX:BDA)

Market cap: AU$49.25 million

BOD Australia is focused on cannabis and hemp-related products. It develops, distributes and markets health and skincare products created using plant-based extracts in Australia. The company secured a foothold in the European cannabis market in 2020 with a AU$200,000 purchase order for four Swiss-branded hemp seed oil products to be sold in France, the Netherlands and the UK.

BOD Australia’s reach in Australia ranges from selling prescription and over-the-counter products to more than 1,000 outlets, such as pharmacies, retail stores and healthcare chains. It also has distribution agreements with two pharmacy wholesalers in Australia.

9. IDT Australia (ASX:IDT)

Market cap: AU$42.47 million

One of Australia’s oldest listed life science companies, IDT Australia is a pharmaceutical manufacturing company with extensive experience in the development and production of pharmaceutical products. Through its GMP-compliant facilities, the company provides full-scale services for new drug development, plus scale-up and commercial active drug manufacturing for local and international clients.

IDT Australia’s clients include Cann Group; IDT Australia is the manufacturer of the medical cannabis products that are a part of two of Cann Group’s export supply agreements with European and UK partners.

10. MMJ Group Holdings (ASX:MMJ)

Market cap: AU$31.04 million

MMJ Group Holdings has a wide range of cannabis investments, including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, retail and research and development.

Among other companies, it has invested in Harvest One Cannabis (TSXV:HVT,OTCQB:HRVOF), which develops health and wellness products; Fire & Flower Holdings (TSXV:FAF,OTCQX:FFLWF), a recreational cannabis retailer that’s developed a variety of cannabis products and accessories; and MediPharm Labs (TSXV:LABS,OTQQX:MEDIF), a cannabis extraction company that received its cannabis oil production licence from Health Canada in 2018. MediPharm Labs has launched cannabis extraction services in Australia.

Investor takeaway

The presence of these ASX-listed cannabis companies shows that the cannabis industry in Australia is undoubtedly growing, as are investment opportunities in Australia’s cannabis industry. While recreational marijuana remains illegal in the land down under, the medical cannabis industry is thriving, making that side of the sector worth considering.

So far, Australia has no timeline attached to the legality of recreational use of marijuana, but it will be a story to watch over the coming years for those interested in the space.

Keep reading... Show less

Legal cannabis is spreading. According to a new report by Grand View Research, the global legal marijuana market is expected to reach US$73.6 billion by 2027 with a compound annual growth rate of 18.1 percent.

A survey of over 1,000 US consumers found that the modern cannabis user is largely representative of the general population. Moreover, cannabis consumption today blurs the lines between strictly recreational or medical. In fact, more than 50 percent of consumers report using cannabis for both purposes. As THC and CBD products make their way into an even wider array of product categories, our frame of reference for the modern cannabis user will continue to evolve.

In 2019, the medical cannabis market took home a leading revenue share of 71 percent, driven by the widespread adoption of cannabis as a pharmaceutical alternative for a wide range of conditions, including cancer, arthritis, Parkinson’s disease and more. A growing need for effective pain management therapies is expected to boost product demand even further.

This INNspired Article is brought to you by:

Khiron Life Sciences Corp. (TSXV:KHRN) is a vertically-integrated medical cannabis company fully licensed to conduct its core operations in Colombia.Send me an Investor Kit

Major telehealth platforms in the medical cannabis industry

Telehealth represents the intersection between innovative technology and the forefront of medical science. While remote medical practice saw its beginnings more than half a century ago, recent technological advancements have connected more patients to physicians than ever before.

In the US, platforms like NuggMD and IndicaMD provide patients with an online medical cannabis card that enables remote purchase of the drug. Patients can meet with physicians over secure video chat and can be approved to access cannabis within minutes. Physicians typically follow-up with patients by email, recommending the types of cannabis that would best alleviate their ailments and ensuring that they don’t purchase the wrong products. Other platforms exist to oversee the rapid delivery of cannabis and hemp products to patients across participating states.

Other parts of the world are undergoing the same transition. It has been more than eight years since Colombia — a country that represents more than a quarter of the world’s total export quotas — decriminalized the possession of small amounts of the drug, and roughly four years since the country legalized medical cannabis. In 2019, Colombia’s Constitutional Court overruled a ban on the public consumption of cannabis, which many considered a stepping stone toward full legalization. Recently, Colombia became one of the first countries in the world to extend national health insurance for patients requiring medical cannabis as a first-line therapy.

Khiron Life Sciences (TSXV:KHRN) was the first firm in Colombia authorized to sell both high and low THC formulations of medical cannabis. The company owns a telehealth platform that has accounted for over 5,600 medical cannabis prescriptions issued to date. Additionally, in June 2020 the company’s Doctor Zerenia telehealth platform was responsible for 14 percent of Khiron’s total medical consultations.

Since becoming the first company to fill medical cannabis prescriptions in Colombia, Khiron reports that 92 percent of its patients have experienced a marked improvement in their primary condition after four months of treatment. In light of these results, the Government of Colombia issued a directive that Khiron’s medical cannabis products and clinic services be covered by the country’s major health insurance providers. While countries such as Germany and the Czech Republic have taken similar legislative actions, a key difference in Colombia is that cannabis is considered a first line therapy with a vast array of applicable medical conditions. With more than 94 percent of Colombia’s population carrying health insurance policies, Colombia is quickly becoming one of the most favourable jurisdictions in the world for patient access; moreover, it has been shown that patient uptake is significantly increased by insurance coverage.

The next step forward for telehealth platforms includes opportunities such as virtual patient education and the fast, reliable delivery of essential drugs such as medical marijuana. Virtual care is also expected to expand across different types of patients, including those requiring intensive care. In the wake of the COVID-19 pandemic, many long-term care facilities have already adapted remote patient monitoring to maintain the safety of staff and patients.

The focus: Accessibility and improving patient outcomes

Medical marijuana has the power to improve patient outcomes across demographics. In the wake of groundbreaking research, patients, physicians and retailers are working together to increase the drug’s accessibility for patients who require relief from a range of health conditions. Telehealth platforms have been instrumental in not only increasing accessibility to medical marijuana, but also in improving quality of life across diverse populations of people.

A recent study completed by Canopy Growth (NASDAQ:CGC,TSX:WEED) in November 2020 found the absence of long-term toxicity despite long-term usage of CBD in a preclinical model, supporting the advancement of recent initiatives aimed at discovering CBD’s full range of therapeutic benefits. While CBD and tetrahydrocannabinol (THC) offer many of the same benefits, high levels of THC are responsible for most of cannabis’s psychoactive effects.

While the chronic pain segment dominated the medical cannabis market in 2019, application toward mental illness is expected to witness the fastest growth over the seven-year forecast period. Worldwide, a growing number of people suffer from depression, anxiety and other debilitating mental conditions with few low-risk pharmaceutical alternatives.

Medical cannabis is also becoming more popular among older adults. A recent study highlighted that cannabis use among individuals aged 65 and older has been steadily increasing, a trend that is consistent with reports from physicians who recommend cannabis in their daily practices. In the face of growing public acceptance and reduced stigma, we are beginning to see an increasing number of older adults rely on cannabis for relief against chronic pain, insomnia, neuropathy, anxiety and other conditions that traditionally call upon pharmaceuticals.

Much of the momentum in the medical cannabis market can be owed to the rise of telehealth platforms and health digitization efforts, increasing ease of access and promoting transparency. Over the next decade, legalization, increased awareness and the rise of remote medicine are expected to facilitate growth, creating lucrative opportunities for market stakeholders.

Takeaway

Telehealth platforms represent one of the easiest ways for patients, providers and retailers to collaborate remotely and fulfill needs faster. As more physicians and policymakers begin to recognize digital health tools as an advantage for maximizing efficiency and safety in health care, existing medical cannabis platforms are well-positioned to take advantage of a large-scale digital transition.

Keep reading... Show less

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less